FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2606732388> ?p ?o ?g. }

• W2606732388 endingPage "43616" @default.
• W2606732388 startingPage "43602" @default.
• W2606732388 abstract "// Craig T. Wallington-Beddoe 1,2,3 , Melissa K. Bennett 1,2,3 , Kate Vandyke 2,3,4 , Lorena Davies 1,2 , Julia R. Zebol 1,2 , Paul A.B. Moretti 1,2 , Melissa R. Pitman 1,2 , Duncan R. Hewett 3,4 , Andrew C.W. Zannettino 1,2,3,4,* and Stuart M. Pitson 1,2,3,* 1 Center for Cancer Biology, University of South Australia, Adelaide, Australia 2 SA Pathology, Adelaide, Australia 3 School of Medicine, University of Adelaide, Australia 4 South Australian Health and Medical Research Institute, Adelaide, Australia * Co-senior authorship of this article Correspondence to: Andrew C.W. Zannettino, email: // Stuart M. Pitson, email: // Keywords : myeloma, endoplasmic reticulum, proteasome inhibitor, sphingosine kinase Received : March 29, 2017 Accepted : April 04, 2017 Published : April 14, 2017 Abstract The proteasome inhibitor bortezomib has proven to be invaluable in the treatment of myeloma. By exploiting the inherent high immunoglobulin protein production of malignant plasma cells, bortezomib induces endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), resulting in myeloma cell death. In most cases, however, the disease remains incurable highlighting the need for new therapeutic targets. Sphingosine kinase 2 (SK2) has been proposed as one such therapeutic target for myeloma. Our observations that bortezomib and SK2 inhibitors independently elicited induction of ER stress and the UPR prompted us to examine potential synergy between these agents in myeloma. Targeting SK2 synergistically contributed to ER stress and UPR activation induced by bortezomib, as evidenced by activation of the IRE1 pathway and stress kinases JNK and p38MAPK, thereby resulting in potent synergistic myeloma apoptosis in vitro . The combination of bortezomib and SK2 inhibition also exhibited strong in vivo synergy and favourable effects on bone disease. Therefore, our studies suggest that perturbations of sphingolipid signalling can synergistically enhance the effects seen with proteasome inhibition, highlighting the potential for the combination of these two modes of increasing ER stress to be formally evaluated in clinical trials for the treatment of myeloma patients." @default.
• W2606732388 created "2017-04-28" @default.
• W2606732388 creator A5011048271 @default.
• W2606732388 creator A5014761965 @default.
• W2606732388 creator A5032213369 @default.
• W2606732388 creator A5032903954 @default.
• W2606732388 creator A5036169480 @default.
• W2606732388 creator A5038486850 @default.
• W2606732388 creator A5041556642 @default.
• W2606732388 creator A5069969531 @default.
• W2606732388 creator A5073344894 @default.
• W2606732388 creator A5073909939 @default.
• W2606732388 date "2017-04-14" @default.
• W2606732388 modified "2023-10-12" @default.
• W2606732388 title "Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress" @default.
• W2606732388 cites W1543556834 @default.
• W2606732388 cites W1895032340 @default.
• W2606732388 cites W1921751791 @default.
• W2606732388 cites W1963731318 @default.
• W2606732388 cites W1964122630 @default.
• W2606732388 cites W1964328292 @default.
• W2606732388 cites W1970311898 @default.
• W2606732388 cites W1973328408 @default.
• W2606732388 cites W1981515291 @default.
• W2606732388 cites W1984400095 @default.
• W2606732388 cites W1985690624 @default.
• W2606732388 cites W1986737010 @default.
• W2606732388 cites W1996605319 @default.
• W2606732388 cites W1996784003 @default.
• W2606732388 cites W1998974565 @default.
• W2606732388 cites W2000763979 @default.
• W2606732388 cites W2002439304 @default.
• W2606732388 cites W2022845438 @default.
• W2606732388 cites W2026642838 @default.
• W2606732388 cites W2033704414 @default.
• W2606732388 cites W2042963083 @default.
• W2606732388 cites W2044052768 @default.
• W2606732388 cites W2046116275 @default.
• W2606732388 cites W2050991415 @default.
• W2606732388 cites W2055177292 @default.
• W2606732388 cites W2064122617 @default.
• W2606732388 cites W2067883668 @default.
• W2606732388 cites W2072667602 @default.
• W2606732388 cites W2080901528 @default.
• W2606732388 cites W2089743544 @default.
• W2606732388 cites W2091795452 @default.
• W2606732388 cites W2099477221 @default.
• W2606732388 cites W2104039873 @default.
• W2606732388 cites W2108091182 @default.
• W2606732388 cites W2111796864 @default.
• W2606732388 cites W2134496563 @default.
• W2606732388 cites W2142638534 @default.
• W2606732388 cites W2144829096 @default.
• W2606732388 cites W2148812091 @default.
• W2606732388 cites W2153716391 @default.
• W2606732388 cites W2154021753 @default.
• W2606732388 cites W2154516862 @default.
• W2606732388 cites W2160159279 @default.
• W2606732388 cites W2163885294 @default.
• W2606732388 cites W2164239756 @default.
• W2606732388 cites W2167721968 @default.
• W2606732388 cites W2168506663 @default.
• W2606732388 cites W2170420350 @default.
• W2606732388 cites W2172662470 @default.
• W2606732388 cites W2192080449 @default.
• W2606732388 cites W2322898660 @default.
• W2606732388 cites W2586709617 @default.
• W2606732388 cites W4211037848 @default.
• W2606732388 doi "https://doi.org/10.18632/oncotarget.17115" @default.
• W2606732388 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5546428" @default.
• W2606732388 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28467788" @default.
• W2606732388 hasPublicationYear "2017" @default.
• W2606732388 type Work @default.
• W2606732388 sameAs 2606732388 @default.
• W2606732388 citedByCount "35" @default.
• W2606732388 countsByYear W26067323882017 @default.
• W2606732388 countsByYear W26067323882018 @default.
• W2606732388 countsByYear W26067323882019 @default.
• W2606732388 countsByYear W26067323882020 @default.
• W2606732388 countsByYear W26067323882021 @default.
• W2606732388 countsByYear W26067323882022 @default.
• W2606732388 countsByYear W26067323882023 @default.
• W2606732388 crossrefType "journal-article" @default.
• W2606732388 hasAuthorship W2606732388A5011048271 @default.
• W2606732388 hasAuthorship W2606732388A5014761965 @default.
• W2606732388 hasAuthorship W2606732388A5032213369 @default.
• W2606732388 hasAuthorship W2606732388A5032903954 @default.
• W2606732388 hasAuthorship W2606732388A5036169480 @default.
• W2606732388 hasAuthorship W2606732388A5038486850 @default.
• W2606732388 hasAuthorship W2606732388A5041556642 @default.
• W2606732388 hasAuthorship W2606732388A5069969531 @default.
• W2606732388 hasAuthorship W2606732388A5073344894 @default.
• W2606732388 hasAuthorship W2606732388A5073909939 @default.
• W2606732388 hasBestOaLocation W26067323881 @default.
• W2606732388 hasConcept C126322002 @default.
• W2606732388 hasConcept C139447449 @default.
• W2606732388 hasConcept C158617107 @default.
• W2606732388 hasConcept C170493617 @default.

• next